On one hand, Aβ was shown to impair insulin-PI3K-AKT signaling [2], [45]–[47] and insulin treatment was reported to improve cognitive function in patients with early AD [48], while on the other hand, AD transgenic mice with reduced insulin signaling were reported to be protected against cognitive decline [49]. Here, AKT1 is linked to Alzheimer disease.